APX005M: Ph I/II started

Apexigen began an open-label, U.S. Phase I/II trial to evaluate intratumoral APX005M given every 3 weeks for up to 4 doses plus IV Keytruda pembrolizumab in about 41 patients. The Phase I portion will...